Loading...
MITO logo

Stealth BioTherapeutics CorpNasdaqGM:MITO Rapporto sulle azioni

Cap. di mercato US$23.5m
Prezzo delle azioni
n/a
Il mio valore equo
Non disponibile
1Y-68.0%
7D-0.1%
1D
Valore del portafoglio
​
Vista

Stealth BioTherapeutics Corp

Report azionario NasdaqGM:MITO

Capitalizzazione di mercato: US$23.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stealth BioTherapeutics (MITO) Panoramica del titolo

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Maggiori dettagli

MITO analisi fondamentale
Punteggio fiocco di neve
Valutazione2/6
Crescita futura0/6
Prestazioni passate0/6
Salute finanziaria0/6
Dividendi0/6

Premi

Gli utili sono cresciuti del 14.4% all'anno negli ultimi 5 anni

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Patrimonio netto negativo

Non ha una capitalizzazione di mercato significativa ( $24M )

Gli azionisti sono stati diluiti nell'ultimo anno

+ 2 più rischi

MITO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Stealth BioTherapeutics Corp

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Stealth BioTherapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.32
Massimo di 52 settimaneUS$1.03
Minimo di 52 settimaneUS$0.16
Beta1.46
Variazione di 1 mese1.75%
Variazione a 3 mesi3.76%
Variazione di 1 anno-68.00%
Variazione a 3 anni-95.86%
Variazione a 5 annin/a
Variazione dall'IPO-97.31%

Notizie e aggiornamenti recenti

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.

Recent updates

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.
Seeking Alpha • Jul 11

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

A clinical-stage biotechnology company, Stealth BioTherapeutics (NASDAQ:MITO) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements.  Company requests an appeal, trading of the company's ADS will be suspended at the opening of business on July 18, 2022. Shares +1.1% after hours
Articolo di analisi • Dec 31

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Stealth BioTherapeutics Corp ( NASDAQ:MITO ) shareholders should be happy to see the share price up 15% in the last...

Rendimenti per gli azionisti

MITOUS BiotechsUS Mercato
7D-0.1%1.0%1.3%
1Y-68.0%34.2%27.7%

Ritorno vs Industria: MITO ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 34.2 % nell'ultimo anno.

Rendimento vs Mercato: MITO ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.7 % nell'ultimo anno.

Volatilità dei prezzi

Is MITO's price volatile compared to industry and market?
MITO volatility
MITO Average Weekly Movement1.5%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Prezzo delle azioni stabile: MITO non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale di MITO è diminuita da 14% a 2% nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
200638Reenie McCarthywww.stealthbt.com

Stealth BioTherapeutics Corp Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Stealth BioTherapeutics con la sua capitalizzazione di mercato?
MITO statistiche fondamentali
Capitalizzazione di mercatoUS$23.54m
Utili (TTM)-US$52.53m
Ricavi(TTM)n/a
0.0x
Rapporto P/S
-0.4x
Rapporto P/E

MITO è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MITO Conto economico (TTM)
RicaviUS$0
Costo del fatturatoUS$0
Profitto lordoUS$0
Altre speseUS$52.53m
Utili-US$52.53m

Ultimi utili riportati

Dec 31, 2021

Prossima data di guadagno

n/a

Utile per azione (EPS)-0.71
Margine lordo0.00%
Margine di profitto netto0.00%
Rapporto debito/patrimonio netto-30.1%

Come si è comportato MITO nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2022/11/16 12:26
Prezzo dell'azione a fine giornata2022/11/15 00:00
Utili2021/12/31
Utili annuali2021/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Stealth BioTherapeutics Corp è coperta da 9 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI